Stock FRLN FREELINE THERAPEUTICS HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Freeline Therapeutics Holdings plc

Equities

FRLN

US35655L2060

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Spur Therapeutics Completes Enrollment in Phase 1/2 Galileo-1 Trial of Flt201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial
CI
Freeline Therapeutics Announces New Name and Brand
CI
Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.
CI
Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting
CI
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
AQ
Syncona’s Takeover of Freeline Therapeutics Becomes Effective
MT
Freeline Therapeutics Holdings plc Announces Resignation of Julia Gregory, Martin Andrews, Jeffrey Chodakewitz, Colin Love and Paul Schneider from the Board
CI
Acquisition of Freeline by Syncona Becomes Effective
AQ
Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index
CI
Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc.
CI
Freeline shareholders approve Syncona acquisition
AN
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona
MT
Freeline Shareholders Approve Acquisition by Syncona
AQ
Syncona says Freeline trial for Gaucher disease treatment positive
AN
European Equities Traded in the US as American Depositary Receipts Gain Friday
MT
Hemophilia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics
AQ
Freeline Therapeutics : Reports Second Quarter 2023 Financial Results and Business Highlights - Form 6-K
PU
Freeline Therapeutics Holdings plc Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
FREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN
BU
HC Wainwright Downgrades Freeline Therapeutics to Neutral From Buy, Adjusts Price Target to $6.50 From $15
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FRLN Stock
  4. News Freeline Therapeutics Holdings plc